PATZ1 Is a DNA Damage-Responsive Transcription Factor That Inhibits p53 Function

Area of Science:

• Molecular Biology
• Cell Biology
• Cancer Research

Background:

• Cellular insults trigger p53 protein accumulation, and its loss promotes tumorigenesis, necessitating tight p53 control.
• The BTB/POZ domain transcription factor PATZ1 (MAZR) is known for its suppressor functions in T lymphocytes.
• The precise regulatory mechanisms governing p53 stability and function are critical for preventing cancer development.

Purpose of the Study:

• To investigate the novel role of PATZ1 (MAZR) as a regulator of the p53 pathway.
• To determine if PATZ1 functions as an inhibitor of p53 protein activity.
• To elucidate the impact of PATZ1 on cellular processes such as proliferation, adhesion, and morphogenesis.

Main Methods:

• Transcriptome sequencing (RNA-Seq) to analyze gene expression in PATZ1-deficient cells.
• Real-time cell growth rate analysis to assess proliferative capacity.
• Co-immunoprecipitation and chromatin immunoprecipitation assays to study protein interactions and DNA binding.

Main Results:

• PATZ1 acts as a novel inhibitor of p53 protein, marking its gene as a proto-oncogene.
• PATZ1-deficient cells exhibit reduced proliferative capacity and altered expression of p53 target genes.
• PATZ1 directly binds to p53, inhibiting p53-dependent transcription activation by excluding p53 from DNA binding.
• Doxorubicin treatment, which induces DNA damage, leads to PATZ1 loss and p53 accumulation.

Conclusions:

• PATZ1 is a crucial regulator of the p53 pathway, functioning as an inhibitor of p53.
• The interaction between PATZ1 and p53 is critical for maintaining cellular homeostasis and preventing uncontrolled proliferation.
• PATZ1's role as a proto-oncogene highlights its significance in cancer development and suggests potential therapeutic targeting.